Literatur
-
1
Ajiro Y, Hagiwara N, Katsube Y, Sperelakis N, Kasanuki H.
Levosimendan increases L-type Ca(2+) current via phosphodiesterase-3 inhibition in human cardiac myocytes.
Eur J Pharmacol.
2002;
435
27-33
-
2
Cleland J G, Ghosh J, Freemantle N. et al .
Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure.
Eur J Heart Fail.
2004;
6
501-508
-
3
Edes I, Kiss E, Kitada Y. et al .
Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart.
Circ Res.
1995;
77
107-113
-
4
Follath F, Cleland J G, Just H. et al .
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
Lancet.
2002;
360
196-202
-
5
Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier L S, Just H.
Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.
Circulation.
1998;
98
2141-2147
-
6
Hoppe U C, Böhm M, Dietz R. et al .
Leitlinien zur Therapie der chronischen Herzinsuffizienz. Im Auftrag der Deutschen Gesellschaft für Kardiologie.
Z Kardiol.
2005;
94
488-509
-
7
Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen P J.
Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
Int J Clin Pharmacol Ther.
2002;
40
465-471
-
8
Kopustinskiene D M, Pollesello P, Saris N E.
Potassium-specific effects of levosimendan on heart mitochondria.
Biochem Pharmacol.
2004;
68
807-812
-
9
Moiseyev V S, Poder P, Andrejevs N. et al .
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: A randomized, placebo-controlled, double-blind study (RUSSLAN).
Eur Heart J.
2002;
23
1422-1432
-
10
Ng T M.
Levosimendan, a new calcium-sensitizing inotrope for heart failure.
Pharmacotherapy.
2004;
24
1366-1384
-
11
Nieminen M S, Akkila J, Hasenfuss G. et al .
Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
J Am Coll Cardiol.
2000;
36
1903-1912
-
12
Pollesello P, Ovaska M, Kaivola J. et al .
Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study.
J Biol Chem.
1994;
269
28584-28590
-
13
Slawsky M T, Colucci W S, Gottlieb S S. et al .
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Circulation.
2000;
102
2222-2227
-
14
Swedberg K, Cleland J, Dargie H. et al .
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.
Eur Heart J.
2005;
26
1115-1140
Prof. Dr. med. Uta C. Hoppe
Klinik III für Innere Medizin der Universität zu Köln
Kerpener Straße 62
50937 Köln
Phone: 0221/4785059
Fax: 0221/4787929
Email: Uta.Hoppe@uni-koeln.de
